{
    "address": "Novum, Halsovagen 7, Floor 8, elevator A",
    "city": "Huddinge",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W8837X104",
    "description": "Sprint Bioscience AB is a pharmaceutical company, which engages in the research and development of drug for cancer. The company is headquartered in Huddinge, Stockholm and currently employs 28 full-time employees. The company went IPO on 2014-11-07. The company is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The firm's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company\u2019s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.",
    "employeeTotal": "28.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2014-11-07",
    "isin": "SE0006343745",
    "logo": "https://finnhub.io/api/logo?symbol=SPRINT.ST",
    "marketCapitalization": 152.1387,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Sprint Bioscience AB",
    "phone": "4684114455.0",
    "sedol": "BSJWY66",
    "shareOutstanding": 21.25275,
    "state": "STOCKHOLM",
    "ticker": "SPRINT.ST",
    "weburl": "https://www.sprintbioscience.com/"
}